Mantle cell lymphoma: established therapeutic options and future directions

@article{Lenz2004MantleCL,
  title={Mantle cell lymphoma: established therapeutic options and future directions},
  author={Georg Lenz and Martin P Dreyling and Wolfgang Hiddemann},
  journal={Annals of Hematology},
  year={2004},
  volume={83},
  pages={71-77}
}
During the last few years, new insights into the biology of mantle cell lymphoma have been obtained. However, with a median survival of only 3 years, mantle cell lymphoma remains the lymphoma subtype with the poorest prognosis. At initial diagnosis most patients present with advanced Ann Arbor stage III or IV and conventional chemotherapy hardly alters the continuously declining survival curve. Recently, two prospective randomized studies of the German Low Grade Lymphoma Study Group (GLSG… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 64 references

A (2003) Report of a phase II study of proteasome inhibitor Bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas

  • A Goy, K East, +13 authors Rodriguez
  • Hematol J 4[Suppl
  • 2003
1 Excerpt

Report of a phase II study of proteasome inhibitor Bortezomib in patients with relapsed or refractory indolent and aggressive B - cell lymphomas

  • A Goy, K East, +13 authors A Rodriguez
  • Hematol J
  • 2003

Similar Papers

Loading similar papers…